Glycosylated BODIPY- incorporated Pt(II) metallacycles for targeted and synergistic chemo-photodynamic therapy [dataset]

  1. Durán-Sampedro, Gonzalo 1
  2. Xue, Evelyn Y. 2
  3. Moreno Simoni, Marta 3
  4. Paramio, Celia 3
  5. Torres, Tomás 4
  6. Ng, Dennis K. P. 2
  7. De La Torre, Gema 5
  1. 1 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

  2. 2 (University of Hong Kong)
  3. 3 Universidad Autónoma de Madrid
    info

    Universidad Autónoma de Madrid

    Madrid, España

    ROR https://ror.org/01cby8j38

  4. 4 (Universidad Autónoma de Madrid; Institute for Advanced Research in Chemical Sciences(IAdChem); Instituto Madrileño de Estudios Avanzados (IMDEA-Nanociencia))
  5. 5 (Universidad Autónoma de Madrid; Institute for Advanced Research in Chemical Sciences(IAdChem))
Mostrar afiliaciones +

Editorial: e-cienciaDatos

Año de publicación: 2024

Tipo: Dataset

DOI: 10.21950/PPAP6T GOOGLE SCHOLAR lock_openAcceso abierto editor

Resumen

Pt(II)-BODIPY complexes combine the chemotherapeutic activity of Pt(II) with the photocytotoxicity of BODIPYs. Additional conjugation with targeting ligands can boost the uptake by cancer cells that overexpress the corresponding receptors. We describe two Pt(II) triangles, 1 and 2, built with pyridyl BODIPYs functionalized with glucose (3) or triethylene glycol methyl ether (4), respectively. Both 1 and 2 showed higher singlet oxygen quantum yields than 3 and 4, due to the enhanced singlet-to-triplet intersystem crossing. To evaluate the targeting effect of the glycosylated derivative, in vitro experiments were performed using glucose transporter 1 (GLUT1)-positive HT29 and A549 cancer cells, and noncancerous HEK293 cells as control. Both 1 and 2 showed higher cellular uptake than 3 and 4. Specifically, 1 was selective and highly cytotoxic toward HT29 and A549 cells. The synergistic chemo- and photodynamic behavior of the metallacycles was also confirmed. Notably, 1 exhibited superior efficacy toward the cisplatin-resistant R-HepG2 cells.